EP2114418A4 - ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN - Google Patents

ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN

Info

Publication number
EP2114418A4
EP2114418A4 EP08725393A EP08725393A EP2114418A4 EP 2114418 A4 EP2114418 A4 EP 2114418A4 EP 08725393 A EP08725393 A EP 08725393A EP 08725393 A EP08725393 A EP 08725393A EP 2114418 A4 EP2114418 A4 EP 2114418A4
Authority
EP
European Patent Office
Prior art keywords
picoplatin
dosage form
oral dosage
stabilized oral
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08725393A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2114418A1 (en
Inventor
Alistair J Leigh
Christopher A Procyshyn
Ernest S Y Wong
Christen M Giandomenico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Poniard Pharmaceuticals Inc
Original Assignee
Genzyme Corp
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Poniard Pharmaceuticals Inc filed Critical Genzyme Corp
Publication of EP2114418A1 publication Critical patent/EP2114418A1/en
Publication of EP2114418A4 publication Critical patent/EP2114418A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08725393A 2007-02-09 2008-02-08 ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN Withdrawn EP2114418A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88917107P 2007-02-09 2007-02-09
US88968107P 2007-02-13 2007-02-13
PCT/US2008/001752 WO2008097661A1 (en) 2007-02-09 2008-02-08 Stabilized picoplatin oral dosage form

Publications (2)

Publication Number Publication Date
EP2114418A1 EP2114418A1 (en) 2009-11-11
EP2114418A4 true EP2114418A4 (en) 2013-01-09

Family

ID=39682046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08725393A Withdrawn EP2114418A4 (en) 2007-02-09 2008-02-08 ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN

Country Status (12)

Country Link
EP (1) EP2114418A4 (pt)
JP (1) JP2010518089A (pt)
KR (1) KR20090109129A (pt)
CN (2) CN101678046A (pt)
AU (1) AU2008214202A1 (pt)
BR (1) BRPI0806418A2 (pt)
CA (1) CA2677640A1 (pt)
HK (1) HK1206267A1 (pt)
IL (1) IL200262A0 (pt)
MX (1) MX2009008488A (pt)
RU (1) RU2009133446A (pt)
WO (1) WO2008097661A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20120148661A1 (en) * 2009-04-15 2012-06-14 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
WO2015179847A1 (en) * 2014-05-23 2015-11-26 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
CN107778331B (zh) * 2016-08-27 2020-06-30 鲁南制药集团股份有限公司 一种甲啶铂的提纯方法
CN108864177B (zh) * 2018-04-20 2020-07-28 公安部物证鉴定中心 [2h3]-1-甲氨基-2-苯基丙烷的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
AU2000279614A1 (en) * 2000-02-16 2001-08-27 Yamanouchi Pharmaceutical Co., Ltd Remedies for endothelin-induced diseases
US6939568B2 (en) * 2001-04-23 2005-09-06 Nucryst Pharmaceuticals Corp. Treatment of inflammatory skin conditions
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
AU2003220022A1 (en) * 2002-03-01 2003-09-16 Trustees Of Dartmouth College Compositions and methods for preventing sporadic neoplasia in colon
AU2003251955A1 (en) * 2002-07-16 2004-02-02 Sonus Pharmaceuticals, Inc. Platinum compound
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
AU2008214202A1 (en) 2008-08-14
WO2008097661A1 (en) 2008-08-14
EP2114418A1 (en) 2009-11-11
MX2009008488A (es) 2010-01-15
BRPI0806418A2 (pt) 2011-09-06
IL200262A0 (en) 2010-04-29
RU2009133446A (ru) 2011-03-20
CN104288119A (zh) 2015-01-21
KR20090109129A (ko) 2009-10-19
CA2677640A1 (en) 2008-08-14
CN101678046A (zh) 2010-03-24
JP2010518089A (ja) 2010-05-27
HK1206267A1 (en) 2016-01-08

Similar Documents

Publication Publication Date Title
EP2157864A4 (en) STABILIZED PICOPLATIN DOSAGE FORM
DK2077729T3 (da) Orale probiotiske doseringsformer
LTPA2018014I1 (lt) Farmacinė kompozicija 514
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0810928A2 (pt) "composição farmacêutica"
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0820381A2 (pt) Formulações farmacêuticas
DK2399580T3 (da) Farmaceutiske doseringsformer
EP2321640A4 (en) FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
EP2241304A4 (en) ORAL DENTAL COMPOSITION
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
EP2236149A4 (en) MEDICAL COMPOSITION
DK2367542T3 (da) Orale doseringsformer af bendamustin
EP2114418A4 (en) ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN
EP2044926A4 (en) ORAL COMPOSITION FOR DENTAL PURPOSES
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
DK2131818T3 (da) Ny doseringsform
PT2271348T (pt) Formulação de comprimido oral de composto de tetraciclina
DK2271321T3 (da) Farmaceutisk sammensætning 271
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121211

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 55/02 20060101ALI20121205BHEP

Ipc: A61K 33/24 20060101AFI20121205BHEP

Ipc: A61K 9/28 20060101ALI20121205BHEP

Ipc: A61K 31/28 20060101ALI20121205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20130905